Author:
Omolehinwa Temitope T.,Akintoye Sunday O.,Gabinskiy Marta,Lo Re Vincent,Mupparapu Mel,Urbina Rosa,Schaubel Douglas E.,Corby Patricia M.
Abstract
Abstract
Background
Long-term antiretroviral therapy (ART) perpetually suppresses HIV load and has dramatically altered the prognosis of HIV infection, such that HIV is now regarded as a chronic disease. Side effects of ART in Patients With HIV (PWH), has introduced new challenges including “metabolic” (systemic) and oral complications. Furthermore, inflammation persists despite great viral load suppression and normal levels of CD4+ cell count.
The impact of ART on the spectrum of oral diseases among PWH is often overlooked relative to other systemic complications. There is paucity of data on oral complications associated with ART use in PWH. This is in part due to limited prospective longitudinal studies designed to better understand the range of oral abnormalities observed in PWH on ART.
Methods
We describe here the study design, including processes associated with subject recruitment and retention, study visit planning, oral health assessments, bio-specimen collection and preprocessing procedures, and data management and statistical plan.
Discussion
We present a procedural roadmap that could be modelled to assess the extent and progression of oral diseases associated with ART in PWH. We also highlight the rigors and challenges associated with our ongoing participant recruitment and retention.
A rigorous prospective longitudinal study requires proper planning and execution. A great benefit is that large data sets are collected and biospecimen repository can be used to answer more questions in future studies including genetic, microbiome and metabolome-based studies.
Trial registration
National Institute of Health Clinical Trials Registration (NCT) #: NCT04645693.
Funder
National Institute of Dental and Craniofacial Research
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Nachega JB, Scarsi KK, Gandhi M, Scott RK, Mofenson LM, Archary M, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023;10(5):e332–42.
2. World Health Organization WHO. HIV and AIDS (who.int). In: Newroom factsheet detail. 2023. https://www.who.int/news-room/fact-sheets/detail/hiv-aids. Acessed 6 Oct 2023.
3. Taiwo B, Barcena L, Tressler R. Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy. Current HIV/AIDS Rep. 2013;10(1):21–32.
4. Heron SE, Elahi S. HIV Infection and Compromised Mucosal Immunity: Oral Manifestations and Systemic Inflammation. Front immunol. 2017;8:241.
5. Alberti KG, Zimmet P, Shaw J, Group I. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–62.